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Abstract 
Activated T-lymphocytes either stimulate or inhibit osteoclastogenesis from 
hematopoietic progenitors in different experimental models. To address this 
controversy, we used several modes of T-lymphocyte activation in osteoclast 
differentiation – mitogen-pulse, anti-CD3/CD28 stimulation, and in vivo and in vitro 
alloactivation. Osteoclast-like cells were generated from non-adherent immature 
hematopoietic monocyte/macrophage progenitors in murine bone-marrow in the 
presence of receptor activator of NF-κB ligand (RANKL) and monocyte-macrophage 
colony-stimulating factor (M-CSF). All modes of in vivo and in vitro T-lymphocyte 
activation and both CD4- and CD8-subpopulation produced similar inhibitory effects on 
osteoclastogenesis paralleled by enhanced dendritic cell differentiation. Osteoclast-
inhibitory effect was associated with T-lymphocyte activation and not proliferation, and 
could be replaced by their culture supernatants. The stage of osteoclast differentiation 
was crucial for the inhibitory action of activated T-lymphocyte on osteoclastogenesis, 
since the suppressive effect was visible only on early osteoclast progenitors but not on 
committed osteoclasts. Inhibition was specifically associated with increased 
granulocyte-macrophage colony-stimulating factor (GM-CSF) expression by the 
mechanism of progenitor commitment toward lineages other than osteoclast because 
activated T-lymphocytes downregulated RANK, CD115, c-Fos and calcitonin receptor 
expression, and increased differentiation towards CD11c-positive dendritic cells. 
Activated T-lymphocyte inhibitory role in osteoclastogenesis, confirmed in vitro and in 
vivo, mediated through GM-CSF release, may be used to counteract activated bone 
resorption mediated by T-lymphocyte-derived cytokines in inflammatory and immune-
disorders. We also demonstrated the importance of alloactivation in osteoclast 
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differentiation and the ability of cyclosporine A to abrogate T-lymphocyte inhibition of 
osteoclastogenesis, thereby confirming the functional link between alloreaction and 
bone metabolism. 
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Introduction 
T-lymphocytes play an important role in the regulation of bone metabolism, particularly 
the bone resorption by osteoclasts [1-4]. However, the reports on activated T-
lymphocyte effects on osteoclastogenesis are still controversial. Activation of T-
lymphocytes in different experimental models or human diseases has mostly been 
shown to stimulate osteoclast differentiation and bone resorption by production of 
cytokines such as receptor activator of NF-κB ligand (RANKL), interleukin (IL)-6, IL-
7, IL-17 and tumor necrosis factor (TNF)-α [2,5-9]. On the other hand, T-lymphocytes 
secrete interferon (IFN)-γ, IL-4, IL-10, IL-13, and granulocyte-macrophage colony-
stimulating factor (GM-CSF), which mediate the inhibition of osteoclastogenesis from 
hematopoietic progenitors [2,5,10-14]. Although some of those inhibitory cytokines 
have been associated with T-lymphocyte activation, various in vitro modes of T-
lymphocyte activation differentially affect osteoclastogenesis [2,8,10,12], and most in 
vivo models report the enhanced osteoclast formation upon T-lymphocyte activation 
[3,6,15,16]. 
T-lymphocytes have a role not only in osteoclast activation and bone resorption but also 
in modulation of multipotent monocyte/macrophage progenitor differentiation towards 
either bone or immune lineage, which is determined by ligand binding to cell-surface 
receptors, particularly receptor activator of NF-κB (RANK) for osteoclasts and Toll-like 
receptors (TLRs) for mononuclear phagocytes [17]. The interaction of RANK, 
expressed on osteoclast progenitors, with its ligand RANKL is crucial for 
osteoclastogenesis in the presence of monocyte-macrophage colony-stimulating factor 
(M-CSF) [6,7,18-20]. At the level of cell signaling, both RANK and TLRs activate the 
dimeric transcription factors NF-κB and activator protein (AP)-1. Transcription factor 
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c-Fos, a component of AP-1, plays a positive role in osteoclast but a negative role in 
macrophage and dendritic cell differentiation [17,21,22]. GM-CSF controls the 
bifurcation between osteoclasts and dendritic cells from common progenitors by 
regulating c-Fos expression [22,23]. 
To study the controversial effect of activated T-lymphocytes on osteoclastogenesis we 
used several activation protocols, including in vivo and in vitro alloactivation. 
Activation by any mode suppressed osteoclastogenesis stimulated by RANKL and M-
CSF in murine hematopoietic progenitors. To elucidate the mechanism by which in 
vitro and in vivo activated T-lymphocytes suppress the differentiation towards the 
osteoclast lineage from bone-marrow (BM) hematopoietic progenitors we identified the 
stage at which the suppressive effect was achieved and the expression profile of the 
treated progenitors. In contrast to some other studies, our findings clearly show that 
activated T-lymphocytes have a net inhibitory effect on osteoclast differentiation by 
diverting early hematopoietic progenitors towards dendritic cell differentiation through 
downregulation of RANK and c-Fos. 
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Materials and methods 
 
Subjects and Samples 
Twelve-week old C57BL/6J (H-2b) female mice were used in all experiments. 
Allogeneic CBA/J (H-2k) mice was used for allostimulation. Maintenance of animals 
and all experimental procedures were approved by the Ethics Committee of the Zagreb 
University School of Medicine. 
 
T-lymphocyte preparation 
Murine lymph node cells were depleted of non-T-lymphocyte populations using anti-
CD11b/anti-CD45R monoclonal antibodies (mAbs) (BD Pharmingen, San Jose, CA) 
and further separated by anti-CD4/anti-CD8 mAbs conjugated to magnetic beads (Dynel 
Biotech, Wirral, UK). Separated T-lymphocyte populations had the purity of >90% as 
confirmed by flow-cytometry. 
Immunosuppressant pretreatment consisted of 1 hour-incubation at 37°C [24] with 
various concentrations (2.5 to 40 µg/mL) of cyclosporine A (CsA) (Sigma-Aldrich, 
Saint Louis, MO). 
For activation, T-lymphocytes were pulsed during 15 minutes by concanavalin A (Con 
A) (Sigma-Aldrich), washed, and cultured for 24 hours. In some experiments T-
lymphocytes were activated by a 24 hour-incubation with anti-CD3 (1 µg/mL; Caltag, 
Burlingame, CA) and anti-CD28 mAbs (0.5 µg/mL; BD Pharmingen). To inhibit 
proliferation, T-lymphocytes were treated with mitomycin C (Sigma-Aldrich) (20 min 
at 37°C) after Con A-pulse and 24 hour-culture. T-lymphocyte activation was 
confirmed by the expression of CD71, and changes in
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cytometry [25]. Proliferation was assessed by the colorimetric MTT (Sigma-Aldrich) 
assay. Activated T-lymphocytes were co-cultured with BM cells or cultured alone to 
obtain conditioned medium needed to treat osteoclastogenic cultures (see the paragraph 
Osteoclast-like cell cultures). 
 
In vivo and in vitro alloactivation 
For mixed lymphocyte reaction (MLR), T-lymphocytes were co-cultured with 
allogeneic mitomycin C-treated splenocytes (cell ratio 1:1) for 48 hours [24]. T-
lymphocyte activation and proliferation were confirmed as described for mitogen pulse. 
Conditioned medium of in vitro alloactivated T-lymphocytes was used to treat 
osteoclastogenic cultures. 
C57BL/6J mice were allostimulated in vivo by i.p. injection of allogeneic splenocytes 
(5×107/mouse) followed by foot-pad restimulation with the same cells (107/foot), 10 
days after the first injection [25]. Untreated mice and mice treated with syngeneic 
splenocytes were used as controls. Allostimulated mice provided tibial BM for 
osteoclast cultures and regionally alloactivated (popliteal) lymph node for T-
lymphocyte cultures. In vivo alloactivated T-lymphocytes were co-cultured with BM 
cells or additionally cultured for 24 hours to obtain conditioned medium needed to treat 
osteoclastogenic cultures. 
 
Osteoclast-like cell cultures 
For osteclast-like (OCL) cell generation, BM were cultured overnight (day -1) with 5 
ng/mL rmM-CSF (R&D Systems, Abingdon, UK) in α-MEM/10% FCS (Sigma-
Aldrich) to stimulate monocyte/macrophage lineage [25], followed by harvesting of 
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non-adherent cells as enriched hematopoietic monocyte/macrophage progenitors that are 
not yet committed towards a certain lineage of differentiation. Non-adherent BM cells 
(2×105/well) were plated (day 0) in 48-well plates with rmRANKL (a gift from Amgen, 
Thousand Oaks, Ca) and rmM-CSF (10 ng/mL for both) to stimulate osteoclast 
formation (termed osteoclastogenic cultures), with medium exchange at day 2.5. 
Different numbers of T-lymphocytes (1.2 to 5×105/well) or different volumes of T-
lymphocyte conditioned medium (12.5 to 100%/well) were used to treat BM cultures at 
day 0 or 2.5. In some experiments rmGM-CSF (5 or 10 ng/mL; R&D), neutralizing anti-
GM-CSF or anti- IFN-γ mAbs(1 µg/mL for both; BD Pharmingen) were added to 
osteoclastogenic cultures together with RANKL and M-CSF. At day 5, tartrate-resistant 
acid phosphatase (TRAP) positive multinucleated cells with ≥ three nuclei/cell were 
considered OCL and counted per well using light microscopy. Differentiated OCL cells 
highly expressed calcitonin receptor (CtR). There were no TRAP+ OCL cells in cultures 
without addition of RANKL and M-CSF. 
 
Flow-cytometry 
Non-adherent BM cell differentiation in osteoclastogenic cultures (after 2.5 day-culture) 
was assessed by: PE-anti-CD115 (c-Fms), PE-anti-CD116 (GM-CSF receptor α) 
(eBioscience, San Diego, CA), FITC-anti-CD11b, APC-anti-CD11c (Caltag), and the 
combination of goat-anti-RANK (R&D Systems) with PE-anti-goat Abs. For 
intracellular cytokine staining, T-lymphocyte were treated with Brefeldin A 
(eBioscience), fixed/permeabilized, and stained with the combination of rabbit-anti-
GM-CSF (eBioscience) and PECy5.5-anti-rabbit Abs. Apoptotic and dead cells were 
detected by Annexin V/propidium iodide (PI) staining (BD Pharmingen) according to 
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the manufacturer's recommendation. Results, using FACSCalibur (BD Pharmingen), 
were presented as histograms or dot-plots for 20,000 viable cells/sample. Dead and 
fragmented cells were excluded from the analysis by their properties on correlated 
forward/side scatter, and PI staining. Applied gates and quadrants were adjusted to non-
stained cells and isotype-controls by delineating negative populations to approximately 
101 fluorescence intensity (not shown). 
 
Gene expression analysis 
RNA was extracted using a commercial kit (TriPure; Roche) from harvested T-
lymphocytes (freshly isolated or cultured) or osteoclastogenic cultures (2.5 or 5 day-
culture). Each sample was obtained from ≥ three animals/group. RNA (1 µg) was 
converted to cDNA and amplified (20 ng/well) by quantitative (q)PCR, using specific 
amplimer sets designed by PrimerExpress software (Applied Biosystems, Foster City, 
CA) for mouse RANK, RANKL, osteoprotegerin (OPG), CD115, TNF-related 
apoptosis-inducing ligand (TRAIL), and β-actin with SYBRGreen chemistry (Applied 
Biosystems). Expression of c-Fos, GM-CSF, IFN-γ, CD178 (FasL), CtR and CD116 
was analyzed using commercially available TaqMan assays (Applied Biosystems). 
qPCR reactions (25 µL/well) were conducted in an ABI Prism 7000 Sequence Detection 
System (Applied Biosystems), in quadruplicate, as described previously [26]. According 
to the standard curve, the relative amounts of RNA for target genes were calculated as 
the ratio of the quantity of target gene normalized to β-actin. RNA quantity for control 
sample in each experiment was set as 1 and the relative RNA quantities for other 
samples were calculated in accordance to this value. 
 
 11 
Statistics 
Experiments were performed at least three times and the representative data were shown 
(mean ± SD of four replicates per sample). Statistical analysis of TRAP+ OCL cell 
number was performed using ANOVA and Student-Newman-Keuls post-hock test 
(MedCalc, Mariakerke, Belgium). Relative values of RNA quantity were statistically 
analysed using the comparison of the means t-test with Bonferroni correction for 
multiple-group comparison (MedCalc). For all experimemts, α-level was set at 0.05. 
 12 
Results 
 
Activated T-lymphocytes inhibit murine osteoclast differentiation  
T-lymphocyte were activated by a brief mitogen pulse [27] in order to avoid the 
presence of Con A in the culture supernatants. Activation of T-lymphocytes consistently 
inhibited in vitro osteoclast differentiation in cultures of murine non-adherent BM cells 
supplemented with RANKL and M-CSF (Figure 1A). This was true both for co-cultures 
of activated T-lymphocytes and osteoclast progenitors and for cultures where osteoclast 
progenitors were treated with the supernatants of activated T-lymphocyte cultures 
(Figure 1B). The inhibitory effect was dose-dependent, i.e. reciprocal to the number of 
activated T-lymphocytes or the volume of activated T-lymphocyte conditioned medium. 
In further experiments, we used 0.25×106 T-lymphocytes per well or 50% conditioned 
medium per well, unless stated otherwise.  
Furthermore, we added activated T-lymphocytes or conditioned medium at different 
time points of osteoclastogenic cultures to test if the stage of osteoclast differentiation 
was important for the inhibitory effect of activated T-lymphocytes. Only immature 
monocyte/macrophage progenitors (treatment 0-2.5 days) were sensitive to the 
inhibitory effect of activated T-lymphocytes, whereas committed osteoclast progenitors 
(treatment 2.5-5 days) did not respond to activated T-lymphocytes or conditioned 
medium (Figure 1C). In further experiments, the treatment by activated T-lymphocytes 
or conditioned medium was performed only for the first 2.5 days of osteoclastogenic 
culture. 
To rule out that the effect of activated T-lymphocytes was a consequence of intensive T-
lymphocyte proliferation and media exhaustion upon co-culture with BM cells, we 
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added mitomycin C-treated activated T-lymphocytes to cultures and found a similar 
inhibitory effect on osteoclastogenesis (Figure 1D). Inhibition of osteoclastogenesis was 
not specifically associated with mitogen stimulation, since osteoclastogenesis was 
blocked in BM cultures treated with the supernatant of T-lymphocytes activated by anti-
CD28/CD3 Abs (Figure 1D). Interestingly, both CD4+ and CD8+ T-lymphocyte 
subpopulations were equally effective in the suppression of osteoclastogenesis, similar 
to unseparated T-lymphocytes (Figure 1E). 
 
Inhibition of osteoclastogenesis is achieved by changes in cytokine gene expression by 
T-lymphocytes 
As assessed by qPCR, activation of T-lymphocytes significantly increased the 
expression of several cytokines known to inhibit osteoclastogenesis such as GM-CSF, 
IFN-γ and OPG, with the parallel overexpression of the osteoclastogenic factor RANKL 
(Figure 2). OPG functions as a decoy receptor for RANKL and competes with 
RANK/RANKL binding [28]. Since we found the proportional increase in both 
RANKL and OPG expression upon T-lymphocyte activation (Figure 2), we do not 
believe that OPG is the important anti-osteoclastogenic factor in our model, especially 
because RANKL is exogenously added to the osteoclastogenic cultures and would 
override the inhibitory effect of OPG.  
Treatment of BM cultures with GM-CSF produced a complete inhibition of 
osteoclastogenesis despite the presence of RANKL and M-CSF in the culture medium 
(Figure 3A). The addition of neutralizing anti-GM-CSF Abs in cultures treated with 
activated T-lymphocyte conditioned medium abrogated their inhibitory effect on 
osteoclastogenesis and restored the number of TRAP+ OCL cells to approximately 90% 
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of the control cultures (Figure 3B) (ranging from 50 to 90% in the repeated 
experiments), whereas the addition of anti-IFN-γ Abs did not produce any changes in 
the OCL cell number (data not shown). Therefore we concluded that GM-CSF’s 
osteoclast-inhibitory effect prevailed over the IFN-γ in our in vitro conditions. 
Intracellular cytokine staining confirmed an increased GM-CSF (Figure 3C) production 
by activated T-lymphocytes. Nevertheless, increased GM-CSF by T-lymphocytes was 
not paralleled by increased CD116 expression in osteoclastogenic cultures (data not 
shown).  
The inhibitory effect was achieved by the significant GM-CSF overexpression in two 
major T-lymphocyte subpopulations CD4+ and CD8+ (RNA relative quantity 0.7 ± 0.1 
in unstimulated and 3.8 ± 0.7 in activated CD4+; 0.9 ± 0.2 in unstimulated and 3.4 ± 0.5 
in activated CD8+; compared with 1.0 ± 0.1 in unstimulated and 4.6 ± 0.3 in activated 
unseparated T-lymphocytes; p < 0.01, t-test with Bonferroni correction for multiple-
group comparison), and both subpopulation have been previously shown to produce 
GM-CSF upon activation [29]. GM-CSF expression was specifically associated with T-
lymphocytes, since we found increased GM-CSF RNA only in co-cultures of activated 
T-lymphocytes and non-adherent BM cells and not in non-adherent BM cell cultures 
treated with activated T-lymphocyte conditioned medium (data not shown).  
 
Osteoclast precursors treated with mitogen activated T-lymphocytes or culture 
supernatants express lower level of RANK, CD115 and calcitonin receptor 
We further assessed the expression of RANK and CD115, receptors for essential 
osteoclastogenic factors RANKL and M-CSF respectively [30], and found that the RNA 
for RANK and CD115 were significantly lower in 2.5 day-osteoclatogenic cultures 
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treated with activated T-lymphocytes or conditioned medium compared with control 
cultures (Figure 4). At day 5, the decrease in gene expression was more pronounced for 
RANK than for CD115, and was stronger in cultures treated with activated T-
lymphocytes than with conditioned medium. Moreover, expression of c-Fos, 
transcription factor important for osteoclast lineage commitment [17], and CtR, marker 
of the differentiated osteoclast [21], was suppressed upon treatment with activated T-
lymphocytes or conditioned medium (Figure 4). Flow-cytometry showed a 
downregulation of RANK and CD115 expression on day 2.5 after the addition of 
activated T-lymphocyte conditioned medium to osteoclastogenic cultures (Figure 5A). 
 
Increased GM-CS expression mediates transdifferentiation between osteoclast and 
dendritic lineages 
To test if activated T-lymphocytes could suppress osteoclast differentiation by GM-
CSF-induced differentiation of common monocyte/macrophage progenitors away from 
the osteoclast towards the immune cell lineages, i.e. dendritic cells, we analyzed the 
expression of CD11c, a dendritic lineage marker [22], on non-adherent BM progenitors 
treated with activated T-lymphocyte conditioned medium. Flow-cytometry on day 2.5 
revealed the presence of CD11chigh population and parallel downregulation of RANK 
expression after the treatment with activated T-lymphocyte conditioned medium. 
Furthermore, we detected a decrease in macrophage CD11b+CD11c– cell population, 
and an increase in dendritic Cd11b–CD11c+ and Cd11b+CD11c+ cell populations 
(Figure 5B).  
Since T-lymphocytes may produce many pro-apoptotic molecules upon activation [31], 
we assessed the expression of TRAIL and CD178 in activated T-lymphocytes after 24 
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hour-culture but detected only a weak, insignificant upregulation by qPCR (data not 
shown). In addition, the apoptotic rate in osteoclastogenic cultures did not differ 
between control cultures and cultures treated with activated T-lymphocyte conditioned 
medium (19.5% Annexin V+/PI– cells in cultures treated with unstimulated vs. 18.8% in 
cultures treated with Con A-pulsed T-lymphocyte conditioned medium by flow-
cytometry). Those results confirmed that progenitor commitment towards dendritic 
lineage and not the induction of osteoclast progenitor apoptosis was the major 
mechanism of osteoclast inhibition in our model. 
 
Allogeneic stimulation of T-lymphocytes in vitro and in vivo produces similar effects on 
osteoclastogenesis as activation by mitogen or anti-CD28/CD3 Abs  
In addition to mitogen and anti-CD3/CD28 stimulation, which has been commonly used 
to study the effects on osteoclastogenesis [6,8,12], we also performed T-lymphocyte 
allostimulation in vivo and in vitro. Conditioned medium of T-lymphocytes 
alloactivated in MLR during 48 hours produced factor(s) that decreased the number of 
TRAP+ OCL cells in osteoclastogenic cultures stimulated with RANKL and M-CSF 
(Figures 6A and B). After in vivo allostimulation, we confirmed that the addition of in 
vivo alloactivated T-lymphocytes or conditioned medium to osteclastogenic cultures 
also suppressed osteoclastogenesis (Figure 6C). In addition, the number of TRAP+ OCL 
cells differentiated from tibial non-adherent BM cells in osteoclastogenic cultures of in 
vivo allostimulated mice was significantly lower compared with cultures from control 
mice (Figure 6D). Pattern of RANK and CD115 expression was similar among 
experimental and control groups when allostimulation, anti-CD3/CD28 treatment or 
Con A-pulse were used for T-lymphocyte activation (see Figure 4). All modes of T-
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lymphocyte activation were associated with an approximate 5-6 fold increase in GM-
CSF expression (see Figure 2).  
 
CsA  abrogates inhibitory effect of T-lymphocytes on osteoclastogenesis 
We further tested if immunosuppressants CsA, which inhibits T-lymphocyte activation, 
can overcome the suppression of osteoclastogenesis caused by Con A-pulsed T-
lymphocytes. Since T-lymphocytes and osteoclasts share the sensitivity to many 
common cytokines [1,2,5] and suppressory signals, including CsA [32,33], we wanted 
to separate the effect of CsA on T-lymphocytes from the effect on osteoclast progenitors  
and, therefore, used CsA only for a brief pretreatment of T-lymphocytes and not for 
actual culture [24]. A brief 1 hour-preincubation of T-lymphocytes with different doses 
of CsA (2.5, 10, and 40 µg/mL) were performed prior to Con A-pulse and subsequent 
24 hour-culture. CsA pretreatment of T-lymphocytes abrogated the suppression of 
osteoclastogenesis in a dose-dependent manner. The most pronounced reversal of 
inhibition of osteoclastogenesis was achieved when T-lymphocytes were first pretreated 
with the highest dose of CsA (40 µg/mL), pulsed with Con A, cultured for 24 hours and 
then added as a 50% conditioned medium to osteoclastogenic cultures (Figures 7A and 
B). The reversal of osteoclast inhibition was paralleled by changes in gene expression 
by Con A-pulsed T-lymphocytes, evidenced by an insignificant downregulation of 
RANKL (p > 0.05) and a significant downregulation of GM-CSF (p = 0.0025, ANOVA 
and Student-Newman-Keuls post-hock test) upon immunosuppressant pretreatment 
(Figure 7C).  
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Discussion 
Our study demonstrated that activated T-lymphocytes suppressed hematopoietic cell 
differentiation towards the osteoclast lineage by affecting the lineage commitment of 
early monocyte/macrophage progenitors through the mechanism that involved RANK 
downregulation and c-Fos suppression. In addition to mitogen-pulse and anti-
CD3/CD28 Abs, we used in vitro and in vivo T-lymphocyte alloactivation and showed 
for the first time that these methods also produce inhibition of osteoclastogenesis. The 
stage of osteoclast differentiation was crucial for the inhibitory action of activated T-
lymphocyte on osteoclastogenesis, since the suppressive effect was visible only on early 
osteoclast progenitors when activated T-lymphocytes were added with RANKL and M-
CSF at the beginning of the osteoclastogenic cultures but not on committed osteoclasts. 
The inhibitory effect was specifically associated with T-lymphocyte activation and not 
proliferation, and did not depend on cell-to-cell contact. The important mediator of 
osteoclast inhibition and dendritic lineage stimulation in our study was GM-CSF, 
known to regulate the bifurcation between osteoclast and dendritic cell lineages [22]. 
We found that activated T-lymphocytes upregulated GM-CSF expression and that the 
osteoclast-inhibitory effect of activated T-lymphocytes was abrogated by the addition of 
anti-GM-CSF Abs to osteoclatogenic cultures.  
GM-CSF effect on osteoclastogenesis depends on the experimental model and the 
duration or timing of GM-CSF administration, and was differently reported in various 
animal models in vivo and osteoclast cultures in vitro [11-13,22,32,34-36]. In contrast to 
the study by Wyzga et al [12], who claimed that the mode of T-lymphocyte activation is 
crucial for the final effect on osteoclast differentiation, we confirmed that the stage of 
osteoclast precursors is more important by showing that GM-CSF in the presence of 
 19 
RANKL at the beginning of the osteoclastogenic cultures inhibits osteoclast formation 
through cellular differentiation into dendritic cells, whereas is ineffective after the 
commitment of RANKL-induced differentiation towards osteoclasts. It has already been 
shown that GM-CSF treatment of  early human osteoclast precursors blocks 
osteoclastogenesis [34], with a repression of major genes indicative of osteoclast 
functions [32], but those studies did not investigate activated T-lymphocytes as a 
possible source of GM-CSF in this regulation. Among other effects, GM-CSF inhibits 
c-Fos in osteoclast progenitors, which disrupts the RANK/c-Fos/nuclear factor of 
activated T cells (NFAT)c1 transcriptional cascade critical for osteoclastogenesis [17]. 
IFN-γ also suppresses osteoclastogenesis by disrupting RANKL-induced activation of 
NF-κB and JNK [1,5]. Nevertheless, increased IFN-γ expression by activated T-
lymphocytes was not important in our model, since osteoclast inhibition was achieved at 
the level of decreased RANK expression (upstream of the described IFN-γ action) and 
could not be neutralized by anti-IFN-γ Abs. GM-CSF acts at earlier stages of osteoclast 
differentiation than IFN-γ [1,10,22], supporting our observation of the more important 
role of GM-CSF than IFN-γ in osteoclast inhibition.  
In our experimental in vitro microenvironment, the treatment of early 
monocyte/macrophage BM progenitors with activated T-lymphocytes determined the 
differentiation towards dendritic cells away from the osteoclast lineage, despite the 
presence of RANKL and M-CSF in culture medium. A number of dendritic cell-like 
adherent clusters were observed in BM cultures treated with all types of activated T-
lymphocytes or conditioned medium enriched in T-lymphocyte derived GM-CSF, 
similar to those observed after GM-CSF treatment. In addition, we detected a 
subpopulation of CD11chigh cells characteristic for dendritic lineage, and a shift from 
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macrophage CD11b+CD11c– towards dendritic CD11b–CD11c+ and Cd11b+CD11c+ 
populations in osteoclastogenic cultures treated with activated T-lymphocyte 
conditioned medium, which has not been found in control cultures. This supports a 
previous finding that GM-CSF stimulates osteoclast progenitor proliferation but inhibits 
differentiation, and in combination with RANKL promotes dendritic cell formation 
[22,23,34]. The mechanism underlying the differentiation switch between osteoclast and 
dendritic lineages certainly involves the regulation of transcription factors essential for 
osteoclast formation, including c-Fos [37]. c-Fos expression was downregulated in 
cultures treated by activated T-lymphocytes, showing that osteoclast differentiation is 
inhibited and dendritic cell differentiation reciprocally stimulated through the 
suppression of c-Fos, supporting our hypothesis that progenitor commitment toward 
lineages other than osteoclast is the underlying mechanism of osteoclast inhibition in 
our model.  
By analyzing RANK and CD115 during in vitro differentiation [30], we found that the 
inhibitory effect of activated T-lymphocytes was more pronounced on RANK 
expression compared to CD115 expression. This suggests that downregulation of 
RANK signaling is the major mechanism of activated T-lymphocyte action, since 
RANK expression on hematopoietic progenitors is essential for osteoclast 
differentiation and activation [19-21]. CD115 gene was downregulated in cultures 
treated with activated T-lymphocytes at earlier stages of osteoclast differentiation, 
confirming that CD115 tyrosine kinase provides signals required for survival and 
proliferation of early osteoclast progenitors [21,30]. Studies using different osteoclast 
culture systems reported different findings regarding the expression of CD115, RANK, 
and CD116 in the presence of M-CSF, GM-CSF, or IL-3 [22,32,36,37]. In contrast to 
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showed upregulation of CD115 upon GM-CSF treatment of human mononuclear cell 
cultures [32], we detected a similar CD116 level irrespective of the treatment with 
activated T-lymphocytes, suggesting that the inhibition of osteoclastogenesis is not 
regulated by CD116 expression. 
In addition to T-lymphocyte activation in vitro by mitogen-pulse or anti-CD3/CD28 
Abs, we extended the importance of our findings by showing that T-lymphocytes 
alloactivated in vitro and in vivo also exerted a suppressive net-effect on 
osteoclastogenesis. These results have clinical significance, since bone homeostasis is 
often severely disturbed after organ transplantation that involves T-lymphocyte 
alloactivation [38,39]. Moreover, we confirmed that activated T-lymphocytes can 
suppress osteoclastogenesis in BM in vivo by the experiments where we used in vivo 
alloactivation by i.p. injection and regional foot-pad restimulation with allogeneic cells. 
When we cultured native non-adherent BM cells from these mice, osteoclastogenesis 
was significantly suppressed compared with cultures from unstimulated animals. These 
findings confirmed the complex function of cytokine expression patterns in the interplay 
between T-lymphocytes and osteoclast progenitors in BM environment despite a 
negligible presence of mature T-lymphocytes in BM [4,10]. 
The inhibitory effect of T-lymphocyte activation on osteoclastogenesis was abolished 
by T-lymphocyte pretreatment with immunosuppressant CsA. CsA action leads to the 
inhibition of NFAT and, hence, suppression of the transcription of IL-2 and other 
cytokine genes, including GM-CSF [24,33,40]. T-lymphocyte treatment with CsA prior 
to the Con A-pulse downregulated GM-CSF expression, which is consistent with the 
presence of NFAT response element in the enhancer part of GM-CSF transcription-
control region [13,41]. In addition, we found only an insignificant decrease in RANKL 
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expression after CsA pretreatment, although a previous study reported that CsA potently 
blocked RANKL in T-cell hybridoma A1.1 [7]. Observed changes in the cytokine 
pattern produced by T-lymphocytes upon immunosuppressive treatment may contribute 
to the post-transplantation osteoporosis in patients receiving long term 
immunosuppressive treatment [38,39]. 
Although it is known that the immune system has powerful effects on bone resorption, 
and both immune cells resident in BM and immunocompetent cells in inflammatory 
tissue may interfere with bone metabolism, the exact nature of molecular effects still 
needs to be discovered before we fully understand the complexity of interactions 
between T-lymphocytes and osteoclasts. As a contribution to this aim, our study clearly 
demonstrated the inhibitory role of activated T-lymphocytes on osteoclastogenesis. The 
underlying mechanism involved increased production of GM-CSF, which drives the 
early monocyte/macrophage progenitor lineage commitment towards dendritic cell 
differentiation through the downregulation of RANK expression and c-Fos 
transcription. This may be a significant regulatory loop and a possible therapeutic target 
to counteract the activated bone resorption mediated by T-lymphocyte derived pro-
osteoclastogenic cytokines in inflammatory and immune-disorders. In our study we also 
demonstrated the importance of in vivo and in vitro alloactivation in the regulation of 
osteoclast differentiation, thereby providing the novel evidence of the functional link 
between alloreaction and bone homeostasis. Ability of CsA to block T-lymphocyte 
activation and hence abrogate the inhibitory effect of T-lymphocytes on 
osteoclastogenesis may be important in clinical states associated with CsA treatment 
and contribute to the rapid bone loss that occurs after organ transplantation. 
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Figure legends 
 
Figure 1. Activated T-lymphocytes suppressed murine osteoclast differentiation 
stimulated by RANKL and M-CSF. (A) Photomicrographs of osteoclastogenic non-
adherent bone-marrow cell cultures with α-MEM (control), unstimulated or activated 
(Con A-pulsed) 0.25×106 T-lymphocytes per well (lyT) and corresponding 50% T-
lymphocyte conditioned medium (sup); ×100. Number of TRAP+ osteoclast-like cells 
(OCLs) in non-adherent bone-marrow cell cultures stimulated by RANKL and M-CSF 
after addition of (B) different numbers of T-lymphocytes/well or different volumes of T-
lymphocyte conditioned medium/well; (C) 0.25×106 T-lymphocytes/well or 50% T-
lymphocyte conditioned medium/well at different time-points of culture (duration of 
treatment – days 0 to 2.5, 2.5 to 5 or 0 to 5); (D) 0.25×106 T-lymphocytes/well, 50% T-
lymphocyte conditioned medium/well, or 0.25×106 mitomycin C-treated T-
lymphocytes/well (lyT + MitC); or (E) 50% conditioned medium/well from unseparated 
(lyT), CD4+ or CD8+ T-lymphocytes. Values, mean ± SD (n=4). *, p < 0.01 vs. control 
culture and respective culture treated with unstimulated T-lymphocytes/conditioned 
medium. T-lymphocytes were activated by Con A-pulse, except for (D) where we used 
Con A-pulse or anti-CD3/CD28 treatment. 
 
Figure 2. Activated T-lymphocytes increased the expression of GM-CSF, IFN-γ, 
RANKL and OPG by RT-qPCR. Relative quantity of RNA represents the ratio of 
RNA quantity for the respective gene normalized to the quantity of β-actin in freshly 
isolated T-lymphocytes (lyT nat), or in unstimulated and activated (Con A-pulsed) T-
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lymphocytes cultured for 24 hours. Values, mean ± SD (n=4). *, p < 0.01 vs. control 
group and unstimulated T-lymphocytes. 
 
Figure 3. GM-CSF mediates suppression of osteoclastogenesis by activated T-
lymphocytes. (A) Photomicrographs of osteoclastogenic non-adherent bone-marrow 
cell cultures with α-MEM (control), activated T-lymphocytes conditioned medium 
(sup) or GM-CSF (5 or 10 ng/mL); ×100. (B) Number of TRAP+ osteoclast-like cells 
(OCLs) in non-adherent bone-marrow cell cultures stimulated by RANKL and M-CSF 
after addition of 50% T-lymphocytes conditioned medium with or without 1 µg/mL 
neutralizing anti-GM-CSF Abs. Values, mean ± SD (n=4). *, p < 0.01 vs. control 
culture, culture treated with unstimulated T-lymphocyte conditioned medium and 
culture treated with activated T-lymphocyte conditioned medium plus anti-GM-CSF. 
(C) Flow-cytometric analysis of GM-CSF production by unstimulated T-lymphocytes or 
activated (Con A-pulsed) T-lymphocytes; dot-plots (FSC/PECy5.5-anti-rabbit + rabbit-
anti-GM-CSF).  
 
Figure 4. Addition of activated T-lymphocytes or conditioned medium to murine 
osteoclastogenic cultures stimulated by RANKL and M-CSF decreased the 
expression of RANK, CD115, c-Fos and calcitonin receptor (CtR) by RT-qPCR. 
Osteoclastogenic non-adherent bone-marrow cell cultures, with or without treatment by 
T-lymphocytes (lyT) or conditioned medium (sup) for the first 2.5 days of culture, were 
harvested for RNA extraction after 2.5 or 5 days of culture. Values, mean ± SD (n=4). 
*, p < 0.01 vs. respective time-point of control culture and respective culture treated 
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with unstimulated T-lymphocytes/conditioned medium. **, p < 0.01 vs. only the 
respective control culture. 
 
Figure 5. Addition of activated T-lymphocyte conditioned medium to murine 
osteoclastogenic cultures stimulated by RANKL and M-CSF changed the 
expression of RANK, CD115, CD11c and CD11b by flow-cytometry. Non-adherent 
bone-marrow cells stimulated by RANKL and M-CSF were cultured for 2.5 days in α-
MEM (control, left panel) or in 50% activated T-lymphocyte conditioned medium (lyT 
ConA sup, right panel). Cultures of bone-marrow cells treated with unstimulated T-
lymphocyte conditioned medium (data not shown) were similar to control cultures. (A) 
Histograms (events/PE-anti-RANK and events/PE-anti-CD115); or (B) histograms 
(events/APC-anti-CD11c), arrow indicates the CD11chigh population, and dot plots (PE-
anti-RANK/APC-anti-CD11c, and FITC-anti-CD11b/APC-anti-CD11c). 
 
Figure 6. In vitro and in vivo alloactivated T-lymphocytes suppressed murine 
osteoclast differentiation stimulated by RANKL and M-CSF. (A) Photomicrographs 
of osteoclastogenic non-adherent bone-marrow cell cultures with α-MEM (control), 
unstimulated (lyT) or alloactivated (MLR) 50% T-lymphocyte conditioned medium 
(sup); ×100. Number of TRAP+ osteoclast-like cells (OCLs) in non-adherent bone-
marrow cell cultures stimulated by RANKL and M-CSF after addition of (B) different 
volumes of unstimulated or in vitro allostimulated T-lymphocyte conditioned 
medium/well; or (C) 0.25×106/well or 50% conditioned medium/well of in vivo 
allostimulated popliteal T-lymphocytes, without or with in vitro restimulation for 24 
hours. (D) In vivo allostimulation was performed by i.p. injection and foot-pad 
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restimulation with allogeneic splenocytes. Left pannel, photomicrographs of 
osteoclastogenic non-adherent bone-marrow cell cultures from unstimulated animals or 
from in vivo allostimulated animals, ×100; right pannel, number of TRAP+ OCLs in 
non-adherent bone-marrow cell cultures stimulated by RANKL and M-CSF from 
unstimulated animals or in vivo allostimulated animals. Values, mean ± SD (n=4). *, p < 
0.01 vs. control culture and respective culture treated with unstimulated T-
lymphocytes/conditioned medium (B and C) or culture from unstimulated animals (D). 
**, p < 0.01 vs. in vivo alloactivated but not in vitro restimulated cells. 
 
Figure 7. Cyclosporine A (CsA)-treatment prior to Con A-pulse abrogates the 
inhibitory effect of T-lymphocytes on murine osteoclast differentiation stimulated 
by RANKL and M-CSF. (A) Photomicrographs of osteoclastogenic non-adherent 
bone-marrow cell cultures with α-MEM (control), unstimulated or activated (Con A-
pulsed) T-lymphocyte (lyT) conditioned medium (sup) with or without CsA 
pretreatment; ×100. (B) Number of TRAP+ osteoclast-like cells (OCLs) in non-adherent 
bone-marrow cell cultures stimulated by RANKL and M-CSF after the addition of 50% 
conditioned medium/well of T-lymphocytes pretreated with different concentrations of 
CsA. (C) RT-qPCR analysis of RANKL and GM-CSFexpression in unstimulated and 
activated (Con A-pulsed) T-lymphocytes, with or without CsA (40 µg/mL) 
pretreatment, after 24 hour-culture. Values, mean ± SD (n=4). *, p < 0.01 vs. respective 
unstimulated T-lymphocytes. **, p < 0.01 vs. ConA-pulsed T-lymphocytes without 
CsA-pretreatment. 
 33 
Figure 1. 
 
 34 
Figure 2. 
 
 
 35 
Figure 3. 
 
 
 
 36 
Figure 4. 
 37 
Figure 5. 
 
 38 
Figure 6. 
 39 
Figure 7. 
 
 
 
 
